Market Research Blog – Page 1345 – New Product Development

Global Exosomes Diagnostic and Therapeutic Market Set for Remarkable Growth, Projected to Reach USD 211.6 Million by 2034

The global exosomes diagnostic and therapeutic market is on a robust growth trajectory, with projections indicating a substantial increase from USD 88.56 million in 2024 to an impressive USD 211.6 million by 2034. This remarkable expansion is anticipated to be driven by a Compound Annual Growth Rate (CAGR) of 9.10% over the next decade, underscoring the escalating interest and investment in exosome technology.

Exosomes, the nanoscale extracellular vesicles secreted by cells, are increasingly recognized for their potential in both diagnostic and therapeutic applications. Their ability to carry biomolecules and facilitate cellular communication positions them at the forefront of innovative medical research and development.

Key Drivers of Growth:

Advancements in Technology: Continuous technological advancements are enhancing the capabilities of exosome analysis and utilization, leading to broader applications in diagnostics and therapeutics.
Rising Investment: The growing influx of investment in exosome research is fueling innovations and accelerating the development of new diagnostic tools and therapeutic interventions.
Increased Research Focus: There is a heightened focus on exosomes in academic and clinical research, driven by their potential to revolutionize personalized medicine and disease management.
Expanding Applications: The application of exosomes in various therapeutic areas, including cancer, cardiovascular diseases, and neurological disorders, is broadening their market appeal and driving demand.

The substantial growth forecast for the exosomes diagnostic and therapeutic market reflects a broader trend of increasing reliance on cutting-edge technologies to advance healthcare outcomes. As the market evolves, stakeholders are expected to witness significant advancements that promise to enhance diagnostic precision and therapeutic efficacy.

Key Insights from the Exosomes Diagnostic and Therapeutic Market Report:

Revenue Growth: The industry achieved a revenue of USD 23.3 million in 2018 and grew to USD 72.6 million by 2023, with a notable CAGR of 25.5%.
Product Segmentation: In 2023, the instruments segment held a 25% market share.
Application Segmentation: Diagnostics accounted for 68% of the market share in 2023.
Regional Outlook: The Canada market is projected to expand at a CAGR of 5% through 2034, while the United States is expected to see a CAGR of 4.5%. Germany’s market is anticipated to grow at a rate of 3.8%, with India and China in the Asia Pacific region expected to achieve CAGRs of 9.5% and 10%, respectively.

High Demand for Exosomes Diagnostic and Therapeutic: Uncover the Trends and Insights with Our Detailed Report!

Competitive Landscape:

Biopharma companies are increasingly focused on creating exosome-based therapeutics for a wide range of conditions, and are addressing manufacturing needs through strategic acquisitions and partnerships. For example, in 2021, Lonza acquired the exosome manufacturing unit of Codiak BioSciences. Similarly, CDMOs such as RoosterBio and EXO Biologics are expanding their services to enhance exosome manufacturing capabilities in Europe.

Latest Developments:

July 2023: ExoCoBio acquired BENEV, merging their strengths to accelerate the commercialization of exosome technology globally.
January 2024: Aruna Bio received FDA clearance for its Lead Program AB126, marking the first exosome technology to enter human clinical trials for a neurological indication, highlighting its therapeutic potential.

Key Players:

The exosomes diagnostic and therapeutic market features prominent players including:

Thermo Fisher Scientific
NanoSomix
NX Pharmagen
Malvern Instruments
Capricor Therapeutic
Exosome Diagnostics
Exiqon A/S
System Biosciences
Exosome Sciences
Aegle Therapeutic
AMS Biotechnology
Miltenyi Biotec
Codiak BioSciences Inc.
Lonza Group (HansaBioMed Life Sciences Ltd.)
AcouSort AB
Aethlon Medical, Inc.
AGC Biologics
Anjarium Biosciences AG
Aruna Bio
Brexogen
Capricor Therapeutics
Cells for Cells
Ciloa
ConvEyXO
Others

Market Research Categories:

Products: Instruments, Software, Reagents and Kits
Applications: Diagnostics, Therapeutic
End Users: Hospitals, Cancer Institutes, Diagnostic Centers, Others
Geographic Markets: North America, Europe, Asia Pacific, Middle East and Africa, Latin America

The exosomes diagnostic and therapeutic market is on the brink of transformative growth, driven by technological advancements, strategic collaborations, and a heightened focus on non-invasive diagnostic technologies. With continued innovation and investment, this market is set to revolutionize healthcare delivery and improve patient outcomes worldwide.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Genital Herpes Treatment Market Set for Robust Growth: Projected to Reach USD 3.55 Billion by 2033

The global genital herpes treatment market is on a trajectory of remarkable expansion, with projections indicating substantial growth over the next decade. The market, valued at USD 2.14 billion in 2023, is expected to reach an impressive USD 3.55 billion by 2033. This notable increase reflects a compound annual growth rate (CAGR) of 5.2%, underscoring a thriving sector with ample opportunities.

The rise in market value is attributed to several key factors, including a growing awareness of genital herpes, advancements in treatment options, and an increasing number of individuals seeking effective management solutions for this prevalent condition. As the demand for innovative and effective therapies continues to escalate, the genital herpes treatment market is poised to experience significant advancements and investments.

In response to this upward trend, there has been an intensification of research and development efforts aimed at enhancing treatment options, improving efficacy, and optimizing patient outcomes. Innovations in antiviral drugs, immunotherapies, and gene therapies are gaining momentum, offering new avenues of hope for individuals affected by genital herpes.

“The growing prevalence of genital herpes worldwide calls for innovative approaches in treatment,” remarked Future Market Insights. “We are committed to advancing therapeutic solutions that address the evolving needs of patients, leveraging cutting-edge research to make a meaningful impact in the fight against this condition.”

Key Market Insights:

The global genital herpes treatment market is expected to reach USD 3.55 billion by 2033, driven by a 5.2% CAGR.
The United States held a significant 32.3% value share of the market in 2022, underscoring its dominance in the sector.
Acyclovir emerged as the leading drug type in 2022, capturing a substantial 51.11% market share.
The genital herpes treatment market in Europe accounted for approximately 23.3% of the global share in 2022.
The United Kingdom is projected to experience a 6.9% CAGR in its genital herpes treatment industry during the forecast period.

Competitive Landscape:

The genital herpes treatment market is characterized by strong competition among leading pharmaceutical companies and manufacturers. Established firms specializing in antiviral medications and treatments for infectious diseases dominate the market. These companies leverage their extensive experience, expertise, and resources to develop and market effective genital herpes treatments.

Ongoing research and development activities play a crucial role in driving the market. Companies are investing in the development of new treatment options, including novel antiviral drugs, therapeutic vaccines, and innovative delivery systems. The ability to bring new and effective treatments to market provides these companies with a competitive edge.

Collaboration is also a key factor in the market, with partnerships between research institutions, healthcare organizations, and industry stakeholders becoming increasingly common. These collaborations help in leveraging expertise, accessing additional resources, and expanding market reach, ultimately leading to a competitive advantage.

Intellectual property rights and patents further influence the competitive landscape, offering companies exclusivity and protection for their innovative treatment solutions. Patented drugs may enjoy a period of market exclusivity, enhancing the competitive position of companies in the market.

Discover the Full Insights: Find the Complete Genital Herpes Treatment Market Report

Top Companies Operating in the Market:

Teva Pharmaceutical Industries Ltd.
Abbott Laboratories
Sun Pharmaceuticals Industries Ltd.
Mylan N.V.
Pfizer Inc.
GlaxoSmithKline plc
Dr. Reddy’s Laboratories, Ltd.
Novartis AG
Valeant Pharmaceuticals International Inc.

Market Segmentation:

By Drug Type: Acyclovir, Valacyclovir, Famciclovir
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores
By Route of Administration: Oral, Topical, Injectable
By Indication: HSV-1, HSV-2
By Region: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, The Middle East & Africa

The genital herpes treatment market is set to witness robust growth, driven by innovation and the increasing global prevalence of the condition. As companies continue to invest in new therapeutic solutions, the market is expected to offer significant opportunities for growth and advancement in the coming years.

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Hepatitis B Diagnostic Tests Market Set for Remarkable Growth: Projected to Reach USD 1,744.26 Million by 2033

The global hepatitis B diagnostic tests market is on the brink of substantial expansion, fueled by rising disease incidence, heightened awareness efforts, and rapid advancements in diagnostic technologies. According to recent market analysis, the market, which was valued at USD 872.5 million in 2023, is expected to sustain this valuation through the end.

Looking ahead, the hepatitis B diagnostic tests market is anticipated to experience a robust compound annual growth rate (CAGR) of 6.5% over the next decade. By 2033, the market is projected to achieve a valuation of USD 1,744.26 million, reflecting significant growth and investment potential.

Key factors driving this growth include increased global awareness campaigns about hepatitis B, advancements in diagnostic technologies that offer more accurate and efficient testing, and rising incidences of the disease worldwide. These developments are expected to bolster demand for advanced diagnostic solutions and contribute to the overall market expansion.

The increasing focus on early detection and management of hepatitis B is likely to further accelerate market growth, offering new opportunities for stakeholders in the diagnostic testing industry.

Key Takeaways from the Market Study:

The market for hepatitis B diagnostic tests expanded at a CAGR of 4.5% from 2018 to 2022.
The Hepatitis B Diagnostic Tests market in the United States is expected to surpass 34.7% market share in 2023.
It is predicted that China would take 23.2% of the worldwide market for hepatitis B diagnostic tests in 2023.
By the end of 2023, the market for hepatitis B diagnostic tests in Japan will hold 7.1% of the global market share.
By 2023, it is expected that the market for hepatitis B diagnostic tests in France would increase by 8%.
By 2023, the Hepatitis B Diagnostic Tests market in the United Kingdom is anticipated to have a 7.8% market share.
In 2023, it is anticipated that the market share held by enzyme immunoassay kits will reach 71.90%.
The hospitals segment will expand quickly at a 6.2% CAGR throughout the projection period.

“The hepatitis B diagnostic tests are promoted through public health programs, increasing liver exams, and healthcare marketing, which raises awareness and diagnoses rates,” remarks an FMI analyst.

Get the Latest on Hepatitis B Diagnostic Tests: Our Full Report Highlights Key Trends and Insights!

Competitive Landscape:

Manufacturers frequently explore new geographical areas to increase their market presence. With healthcare organizations and providers all across the world, they create distribution networks and partnerships. Manufacturers can access untapped client bases by diversifying into new markets and areas with a high hepatitis B incidence.

In order to make sure that their goods adhere to local norms and laws, businesses may also apply for regulatory licenses and certifications in other nations.

Prominent players in the Hepatitis B Diagnostic Tests Market are:

Bio-Rad Laboratories, Inc.
DiaSorin S.p.A.
Abbott Laboratories
Meridian Bioscience
bioMérieux SA Inc.
Vista Diagnostics International
Biogate Laboratories Ltd.
Mitra & Co. Ltd.
Siemens Medical Solutions USA, Inc.
General Biologicals Corporation

Product Portfolio:

A healthcare corporation with a wide range of services, Abbott Laboratories has been involved in the creation of medicines, notably antiviral drugs. They have created medications in the past that are used to treat chronic hepatitis B. One such instance is the drug “Hepsera” (generic name: adefovir dipivoxil), that was used in some individuals to prevent the reproduction of the hepatitis B virus.
“Viread,” which is made by Gilead Sciences, Inc., is one of the treatments for hepatitis B that is often used. Tenofovir disoproxil fumarate (TDF), the active component of Viread, is an antiviral drug intended to prevent the hepatitis B virus (HBV) from replicating in people with chronic hepatitis B infection.

Segmentation Analysis of the Hepatitis B Diagnostic Tests Market:

By Product Type:

Enzyme Immunoassay Kits
- Hepatitis B Surface Antigen Test
- Anti-Hepatitis B Surface Antibody Test
- Anti-Hepatitis B Core Antibody Test
Point-of-Care Testing Kits
- Strips
- Cassettes/Cards

By End User:

Hospitals
Clinics
Diagnostic Centers
Home Care

By Region:

North America
Latin America
Western Europe
Eastern Europe
South Asia and Pacific
East Asia
The Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Global Tinnitus Management Market Set for Remarkable Growth, Projected to Reach USD 3.7 Billion by 2033

The global tinnitus management market is on the brink of substantial expansion, driven by increasing awareness and innovative advancements in treatment methodologies. According to a recent report by Future Market Insights, the market, which was valued at USD 2.62 billion in 2023, is projected to grow at a compound annual growth rate (CAGR) of 3.7%. By 2033, the market is expected to reach an impressive USD 3.7 billion.

Tinnitus, characterized by ringing or buzzing sounds in the ears without external stimuli, affects a significant number of individuals worldwide, impacting their quality of life. The growing prevalence of tinnitus, attributed to factors such as ear hair cell destruction, earwax blockage, and increased headphone usage, has propelled the demand for effective management solutions.

Advancements in research and development have led to the introduction of innovative treatments with improved efficacy and reduced side effects. This surge in new treatment options is expected to further accelerate market growth, providing relief to millions suffering from tinnitus globally.

“The tinnitus management market is witnessing robust growth due to advancements in hearing aid technology and heightened R&D activities,” stated Future Market Insights. “As awareness about tinnitus expands and new therapeutic interventions emerge, the market is positioned for accelerated expansion.”

Key market players are well-positioned to capitalize on these opportunities by enhancing their product offerings and expanding their market presence. This growth trajectory underscores the industry’s commitment to meeting the evolving needs of individuals with tinnitus and improving their overall quality of life.

Key Takeaways:

The North America to accelerate its market share by 52.4% between 2023 and 2033.
The Europe surges its market share by 24.7% between 2023 and 2033.
The United States might increase its market share by 50.6% between 2023 and 2033.
During the forecast period, Chinese tinnitus management business to expand at a CAGR of 5%.
From 2023 to 2033, the United Kingdom tinnitus management industry to register at a 2.7% CAGR.
Between 2023 and 2033, the Australian market is to register a CAGR of 3.8%.
Through 2033, the Indian tinnitus management business to record a CAGR of 4.8%.
Device segment of the product category is predicted to have a market share of 93.8% by 2033.
The subjective tinnitus segment to hold a market share of 95.59% in the indication category between 2023 and 2033.
The audiology centers segment to acquire a substantial market share of 37.9% in the distribution channel category between 2023 and 2033.

Elevated Demand for Tinnitus Management: Our Full Report Offers a Thorough Analysis of Trends and Insights!

Competitive Landscape:

The tinnitus management market is fragmented, with many multinational and domestic businesses controlling a sizable portion. Major tinnitus management manufacturers focus on product creation and launch to acquire a competitive advantage in the market.

They are concentrating on growing their regional presence to capture a larger piece of the tinnitus management industry. Product launches and expansions are important market tactics.

Latest Innovations:

Signia Launches Augmented Xperience (AXE) Hearing Aid Platform for Clear Sound in any Environment

To ensure that listeners always hear clear sound, regardless of the listening environment, hearing aid innovator Signia, a top provider of hearing solutions, announced the launch of its novel Augmented Xperience (AXE) hearing aid platform in August 2021.

Shire Acquisition: Takeda Expands Portfolio and Market Presence in PDT, Cancer, Rare Diseases, and GI

Shire plc, a specialist biopharmaceutical business based in the United States, was acquired by Takeda Pharmaceutical business in January 2019. The company to benefit from the acquisition by being able to diversify their product offerings and increase their market share in the fields of PDT, cancer, rare diseases, and GI.

Key Players:

Pfizer Inc.
Sanofi
Teva Pharmaceutical
GlaxoSmithKline
Eli Lilly and Co.
Bayer AG
Takeda Pharmaceutical Company Ltd.
Boehringer Ingelheim
Merck & Co.
Abbivie
Starkey Laboratories, Inc.
GN Hearing A/S
Widex A/S
Oticon Inc.
Neuromod Devices Ltd.
Neuromonics, Inc.
Puretone Ltd.
Signia

Key Segments:

By Product:

Devices
- Sound Masking Devices
- Notched Music Devices
- Hearing Aids
Drugs
- Tricyclic Antidepressants
- Antianxiety
- Anticonvulsants

By Indication:

Subjective Tinnitus
Objective Tinnitus

By Distribution Channel:

Audiology Centers
ENT Clinics
Hospitals
E-Commerce

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa (MEA)

About Future Market Insights (FMI)

Contact Us:

United States Digital Pregnancy Test Kits Market Poised for Steady Growth, Projected to Reach USD 333.2 Million by 2033

The United States digital pregnancy test kits market has demonstrated impressive growth, achieving a valuation of USD 207.6 million in 2023. This upward trajectory is set to continue, with the market expected to expand at a steady Compound Annual Growth Rate (CAGR) of 4.8% from 2023 to 2033, according to the latest research report by Future Market Insights (FMI).

The robust performance of the market underscores the increasing adoption of digital pregnancy test kits, which offer enhanced accuracy and user-friendliness compared to traditional testing methods. As consumer preferences shift towards more reliable and easy-to-use diagnostic tools, the digital pregnancy test kit sector is expected to experience sustained demand and growth.

FMI’s report highlights that the market is projected to reach an impressive USD 333.2 million by the end of the forecast period in 2033. This growth is driven by several factors, including advancements in technology, rising awareness about early pregnancy detection, and an increase in the prevalence of pregnancy planning among women.

“The digital pregnancy test kits market in the United States has shown remarkable growth driven by technological innovation,” said FMI. “Consumers are increasingly preferring digital tests due to their ease of use, reliability, and ability to deliver results quickly and accurately.”

Key market players are focusing on product innovation and strategic partnerships to strengthen their market presence and cater to evolving consumer needs. The competitive landscape is characterized by advancements such as Bluetooth connectivity, smartphone app integration, and digital result display features, which are expected to further fuel market growth in the coming years.

The report also highlights regional trends and consumer behavior insights that are shaping the future trajectory of the digital pregnancy test kits market in the United States. Factors such as increasing awareness about early pregnancy detection and rising healthcare expenditure are anticipated to contribute to market expansion over the forecast period.

Key Takeaways:

Based on product type, branded test kits sub-segment captured a substantial portion of the market share of about 86.65% in 2022.
In 2022, drug stores held around 36% value share in the market for digital pregnancy test kits market in the United States of America by distribution channel.
The United States of America digital pregnancy test kits market amassed a revenue of USD 158.1 million in 2018.
From 2018 to 2022, the market was predicted to secure a CAGR of 4.7%.
The United States of America’s digital pregnancy test kits industry is forecasted to move forward with a momentum of 4.8% from 2023 to 2033.

What is the Level of Market Competition in the United States of America Digital Pregnancy Test Kits Industry?

The United States of America’s digital pregnancy test kits industry is highly competitive, with several key players vying for market share.

The market is characterized by intense competition among established brands as well as the entry of new players. The presence of multiple manufacturers and the availability of a wide range of digital pregnancy test kits contribute to the competitive landscape of the industry.

Companies are continuously striving to differentiate their products through innovative features, advanced technology, accuracy, ease of use, and affordability to gain a competitive edge. Additionally, marketing and advertising campaigns play a crucial role in promoting brand awareness and attracting customers.

The competitive nature of the market fosters a constant drive for improvement and innovation among industry players, ultimately benefiting consumers with a diverse range of options and improved product offerings.

Gain Full Insight: Access the Complete United States of America Digital Pregnancy Test Kits Market Report

Some of the Leading Companies Operating in the Market:

Swiss Precision Diagnostics GmbH
Church & Dwight Co., Inc.
Gregory Pharmaceutical Holdings, Inc.
Mankind Pharma (Lifestar LLC)
Sugentech, Inc.
NTBIO Diagnostics Inc.
Bio-AMD

Market Segmentation by Category:

By Product:

Branded Test Kits
Private Label Test Kits

By Distribution Channel:

Institutional Sales
- Hospital Pharmacies
- Gynaecology Clinics
- IVF Clinics
- Maternity Care Centers
Retail Sales
- Retail Pharmacies
- Drug Stores
- Hypermarkets & Supermarkets
- Online Sales

About Future Market Insights (FMI)

Contact Us:

Global Drug of Abuse Testing Market Set to Reach USD 2.69 Billion by 2033, with a CAGR of 5.3%

The global drug of abuse testing market is poised for significant growth, with an estimated valuation of USD 1.65 billion in 2023, projected to surge to USD 2.69 billion by 2033. This robust expansion reflects a compound annual growth rate (CAGR) of 5.3% over the forecast period, according to recent market research.

The increasing prevalence of substance abuse and the rising need for drug testing in various sectors—including healthcare, law enforcement, and workplace safety—are driving this market growth. Advances in testing technologies, coupled with stricter regulatory frameworks, are also contributing to the upward trend.

A few factors contributing to the global market growth are:

Increase Substance Abuse: The demand for drug abuse testing for prescription and illicit drugs drives the global market. It is significantly used in various settings for drug detection, including schools, workplaces, and rehabilitation centers.
Workplace Safety: Employers across several industries prefer drug testing programs to enhance workplace safety. This testing helps to identify employees under drug influence, which helps to reduce the risk of injuries and accidents.
Sports and Athletics: Drug testing play a key role in maintaining fair competition in sports activities. The government and sports organizations initiate anti-doping, which increases the demand for drug abuse testing to enhance players’ performance.
Advanced Technologies: The rising advanced technologies to develop efficient, accurate, and sensitive drug testing methods fuel the global market. The growing innovations of point-of-care testing, immunoassays, and chromatography techniques drive the global market.
Growing Awareness: The rising awareness of the side effects of drugs and prevention are increasing the adoption of drug abuse testing. Government bodies, healthcare, and NGOs are initiative education campaigns that contribute to expanding the global market.

Key Takeaways:

The drug abuse testing market is estimated to secure a valuation of USD 2.69 billion in 2033 with a CAGR of 5.3% during the forecast period.
In the historical period, the market secured a valuation of USD 1.5 billion in 2022.
The United States dominates the global market by capturing a maximum share of 25.5% during the forecast period.
Germany is significantly driving the global market by registering a share of 4% by 2033.
With a share of 3.3%, Japan is securing a significant share in the global market during the forecast period.

Increased Interest in Drug of Abuse Testing: Explore Our Detailed Report for Key Trends and Insights!

How are Key Players Adding Value in the Global Market?

Several prominent players consolidates the market presence globally. These players are developing innovative products by adopting advanced technologies. They offer improved and high-quality products to their consumers as per their needs.

Key players are adopting various marketing methodologies to elevate the global market. These marketing methodologies are partnerships, mergers, acquisitions, collaborations, product launches, and agreements. The key players are conveniently provided delivery of their products and services through their distribution networks.

They are marketing and promoting their products in social media, online retailers, and offline platforms to increase their sales volume. These players are significantly expanding the market by providing awareness and educating their customers at trade shows, exhibitions, and seminars.

Recent Developments in the Global Market:

Abbott Laboratories offers a variety of drug abuse testing, such as laboratory testing solutions, immunoassays, and point-of-care testing. The company invests in research and development activities to expand its business portfolio.

Other Essential Players in the Global Market are:

Quest Diagnostics
Roche Holding AG
Thermo Fisher Scientific, Inc.
Siemens AG (Siemens Healthineers)
Abbott Laboratories (Alere, Inc.)
Shimadzu Corporation
Express Diagnostics International Inc.
Drägerwerk AG & Co. KGaA
Laboratory Corporation of America Holdings.

Drug of Abuse Testing Market by Category:

By Drug Type:

Psychostimulants
Narcotic
Cannabinoids
Sedatives
Others

By Technique:

Immunoassay
Chromatography
Rapid Testing

By End User:

Hospitals
Diagnostics Laboratories
Forensic Laboratories
Others

By Region:

North America
Latin America
Europe
Asia Pacific
The Middle East and Africa

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Single-Photon Emission Computed Tomography Market Poised for Robust Growth, Projected to Reach USD 4.76 Billion by 2032

The global single-photon emission computed tomography market is on a trajectory of significant growth, fueled by rapid advancements in diagnostic imaging technologies and the rising incidence of cardiovascular diseases. Recent market analysis underscores a promising future for SPECT, with the market’s valuation soaring from USD 2.28 billion in 2021 to an estimated USD 2.45 billion by the close of 2022.

This upward trend is set to continue, with the market projected to expand at a compound annual growth rate (CAGR) of 6.9% over the forecast period from 2022 to 2032. By the end of this period, the global SPECT market is anticipated to reach approximately USD 4.76 billion, reflecting a robust and sustained increase in demand.

Single-photon emission computed tomography is a pivotal nuclear medicine technique that enables 3-D imaging of functional processes within the human body. It utilizes short-lived radioisotopes for non-invasive diagnostic imaging of metabolic processes, playing a crucial role in the detection and management of chronic illnesses.

In 2021, the single imaging gamma cameras segment dominated the global SPECT market with a market share of 75.5%, a trend expected to continue throughout the forecast period. These gamma cameras are integral to SPECT systems, enhancing diagnostic capabilities by providing detailed metabolic and functional data of cells and organs.

The increasing demand for better diagnostic tools, coupled with advancements in organic-specific and dual-modality imaging systems, is driving the expansion of the SPECT market. As healthcare providers prioritize accurate and efficient diagnostic solutions, SPECT technology is poised to play a pivotal role in meeting these demands.

“The global SPECT market is witnessing robust growth driven by technological advancements and the rising burden of cardiovascular diseases,” said FMI. “As we move towards 2032, innovations in imaging systems and enhanced diagnostic capabilities will further accelerate market expansion.”

Key Takeaways: Single-Photon Emission Computed Tomography (SPECT) Market

The global SPECT market reached USD 2.28 billion in 2021 and is expected to reach USD 2.45 billion by 2022.
The market is expected to grow at a CAGR of 6.9% from 2022 to 2032, reaching a valuation of USD 4.76 billion by 2032. This growth is attributed to the rising prevalence of cardiovascular diseases and the demand for better diagnostic tools.
North America, with the USA holding a dominant 38% share in 2021, is expected to continue leading the market due to favorable reimbursement policies for nuclear medicine procedures.
China’s SPECT market, with a 5.3% share in 2021, is projected for healthy growth due to advancements in medical infrastructure, focus on chronic disease management, and government support for cancer research.
Germany, with an aging population and increasing use of radiopharmaceutical diagnostics, is expected to hold a nearly 5% market share due to government funding initiatives.

Stay Ahead with Single-Photon Emission Computed Tomography: Delve into Our Full Report for Extensive Trends and Insights!

Competitive Landscape:

Major players in the single-photon emission computed tomography (SPECT) market are aggressively pursuing market dominance through strategic partnerships, product launches, and expansion efforts. For example:

In November 2020, GE Healthcare acquired Prismatic Sensors AB, a Swedish startup known for its expertise in photon-counting detectors. This acquisition underscores GE Healthcare’s ongoing commitment to advancing photon-counting CT technology.
In May 2022, Mediso Ltd. acquired Bartec Technologies Ltd., a UK-based company specializing in the supply, installation, and support of Nuclear Medicine and Molecular Imaging equipment and accessories.

These moves highlight the proactive strategies employed by industry leaders to strengthen their positions and drive innovation in the SPECT market.

Key Companies Profiled:

Bruker Corp.
DDD-Diagnostic AS
Digmed Corp.
General Electric Co.
Mediso Ltd.
MiE GmbH
MILabs BV
Siemens Healthineers AG
Spectrum Dynamics Medical Inc.
GE Healthcare
CardiArc
Beijing Hamamatsu Photon Techniques INC.
SHENZHEN BASDA MEDICAL APPARATUS CO., LTD.
PNPMed
NuCare Inc.

Key Market Segments Covered in Single-photon Emission Computed Tomography Industry Research:

By Product:

Single Imaging Gamma Cameras
SPECT/CT

By Application:

Cardiology
Oncology
Neurology
Others

By End User:

Hospitals
Diagnostic Imaging Centers
Ambulatory Surgical Centers

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa(MEA)

About Future Market Insights (FMI)

Contact Us:

Global Veterinary Ultrasound Scanner Market Set for Significant Growth, Expected to Reach USD 284.8 million by 2033

The global veterinary ultrasound scanner market is on an impressive growth trajectory, with forecasts indicating a substantial increase in market value over the next decade. According to recent industry reports, the market is anticipated to reach USD 198.1 million by the end of 2023, demonstrating a steady Compound Annual Growth Rate (CAGR) of 3.7% through 2033. This growth trajectory is expected to propel the market to an impressive valuation of USD 284.8 million by the conclusion of the forecast period.

The rise in market value can be attributed to several factors, including advancements in ultrasound technology, increasing adoption of these diagnostic tools in veterinary practices, and a growing focus on animal health and welfare. Veterinary ultrasound scanners play a crucial role in diagnosing and monitoring a range of conditions in animals, making them an essential tool for veterinary professionals worldwide.

Industry experts highlight that ongoing innovations in ultrasound technology, such as enhanced image resolution and portability, are contributing to the increased adoption of these devices. Additionally, the growing emphasis on preventive care and early diagnosis in animals is driving the demand for advanced diagnostic tools.

Key Takeaways from the Market Study:

The market valuation in 2022 was USD 9 million.
Based on product type, portable/handheld ultrasound scanners are expected to dominate at a market share of 86.5% in 2023.
Based on imaging technology, digital imaging technology will register at a market share of 93.7% in 2023.
The veterinary ultrasound scanner market size expanded at 4.6% CAGR between 2018 and 2022.
India is estimated to expand at a CAGR of 5.5% by 2033.
Germany experiences a significant rise, with a CAGR of 2.2% by 2033.

“Technological advancements have largely influenced the veterinary care market and also affected the veterinary ultrasound scanner demand is thus considered one of the major drivers of the veterinary ultrasound scanner market,” comments a Future Market Insights analyst.

Unveil the Veterinary Ultrasound Scanner Surge: Read Our Detailed Report for Essential Trends and Insights!

Drivers of Growth:

Increased awareness and importance of animal healthcare: This includes rising pet ownership, growing concern about zoonotic diseases (diseases transmissible between animals and humans).
Technological advancements: Advancements in ultrasound technology lead to more accurate and efficient diagnoses.
Rising expenditure on animal health: Pet owners are spending more on their pets’ well-being, including diagnostics.
Pet insurance adoption: Increased pet insurance allows for more comprehensive veterinary care, including ultrasound scans.
Government initiatives: Supportive government programs promoting animal health can contribute to market growth.

Competitive Landscape:

The veterinary ultrasound scanner industry boasts a substantial array of market participants. Research and development play a pivotal role among these players, primarily focusing on introducing eco-friendly product lines as a core aspect of their manufacturing endeavors. Furthermore, they employ various expansion strategies, including collaborations, mergers and acquisitions, and diligent exploration of regulatory approvals to bolster their market presence.

Some of the key developments are-

Butterfly Network Inc., a trailblazing digital health firm recognized for its innovative product approach, recently unveiled its latest veterinary ultrasound device. The iQ+ Vet ultrasound introduces a cutting-edge guidance tool and hardware enhancements, promising sharper imaging for improved diagnostics.
Lacuna Diagnostics Inc., a pioneering telemedicine and point-of-care diagnostics company, entered into a comprehensive acquisition agreement with Heska Corporation.

Key Companies Profiled:

Siemens AG
Mindray Medical International Limited
Hitachi Ltd.
Fujifilm Holdings Corporation
General Electric Company
Canon Inc.
Samsung Electronics Co. Ltd.
Esaote SpA
DRAMI?SKI S. A.
IMV Technologies SA

Key Segments of Veterinary Ultrasound Scanners Industry Survey:

By Product Type:

Portable/Hand Held Ultrasound Scanners
Cart Based Ultrasound Scanners

By Imaging Technology:

Digital Imaging Technology
Analog Imaging Technology
Contrast Imaging Technology

By End User:

Veterinary Hospitals
Veterinary Clinics
Animal Breeding and Farms

By Region:

North America
Latin America
Western Europe
Eastern Europe
South Asia and Pacific
East Asia
The Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Global Patient-Controlled Analgesia Pumps Market Set for Robust Growth, Projected to Reach USD 729.1 Million by 2033

The global Patient-Controlled Analgesia (PCA) pumps market is on the brink of substantial expansion, according to a recent market analysis. The report highlights a promising growth trajectory driven by the increasing demand for advanced pain management solutions.

The patient-controlled analgesia pumps market, valued at USD 447 million in 2023, is expected to grow at a robust Compound Annual Growth Rate (CAGR) of 5% over the forecast period. This growth trajectory is set to propel the market to an impressive valuation of USD 729.1 million by 2033.

The surge in market valuation underscores significant opportunities for industry stakeholders, reflecting a burgeoning demand for innovative pain management technologies. As healthcare providers and patients seek more efficient and effective pain control methods, PCA pumps are emerging as a critical component in the management of pain across various medical settings.

This anticipated market expansion highlights the sector’s potential for long-term success and positions PCA pump manufacturers and suppliers at the forefront of a rapidly evolving industry. With increasing investments in technology and a growing focus on patient-centered care, the PCA pumps market is well-positioned for continued growth and innovation.

Global Patient-Controlled Analgesia Pumps Market: Dynamics

The growth of the global patient-controlled analgesia pumps market is influenced by aspects such as various advantages of PCA system over conventional continuous infusion systems, increasing standardization for reducing costs in hospitals, development of quality indicators for patient-controlled analgesia pumps, modernization with a view to reduce errors, increasing adoption of PCA owing to increasing prevalence of cancer, pain and diabetes, rising forward integration and increasing demand for PCA in rental and homecare services.

These factors have contributed to the growth of the global market. On the contrary, lack of skilled manpower and lack of standard usage guidelines and vast product recalls are hampering the growth of the global patient-controlled analgesia pumps market. Various trends have been observed, to name a few, rapid med-tech progress, shifting production base to emerging economies, user-friendly advanced equipment and fragmented market. Opportunities such as increasing production base for smart pumps with bigger drug libraries and expanding production base for PCA, ambulatory and other pumps have been

Key Takeaways:

The electronic PCA pumps segment is expected to account for the largest market share during the forecast period, owing to the increasing adoption of advanced technologies in the healthcare sector.
The hospital segment is expected to dominate the market in terms of revenue, owing to the high demand for PCA pumps in hospitals for the treatment of post-operative pain and chronic pain.
North America is expected to remain the largest market for PCA pumps during the forecast period, owing to the high prevalence of chronic diseases and the high adoption of advanced technologies in the healthcare sector.
Asia Pacific is expected to be the fastest-growing market for PCA pumps during the forecast period, owing to the increasing prevalence of chronic diseases and the rising demand for ambulatory care.

Patient-controlled Analgesia Pumps in Demand: Check Out Our Full Report for a Complete Overview of the Trends and Insights!

Other key trends that are expected to drive the growth of the PCA pumps market include:

The increasing demand for minimally invasive surgeries, which require the use of PCA pumps for pain management.
The growing awareness of the benefits of PCA pumps, such as improved pain control, reduced risk of side effects, and faster recovery.
The development of new and innovative PCA pumps, such as wearable and disposable PCA pumps.

Key Companies Profiled:

Smiths Group plc.
Fresenius Kabi Group,
Hospira (Pfizer Inc.),
Micrel Medical Devices,
Ace Medical Co. Ltd.
Terumo Corporation,
B.Braun Melsungen AG
Baxter International
Becton Dickinson and Company.
BD
ICU Medical

Key Market Segments Covered in Patient-Controlled Analgesia Pumps Industry Research:

By Product:

PCA Pumps
Pump Accessories

By Application:

Chemo Therapy/Oncology
Pediatrics/Neonatology
Gastroenterology
Hematology

By End-User:

Hospitals
Ambulatory Surgical Centers
Home care settings

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa (MEA)

About Future Market Insights (FMI)

Contact Us:

Global Tinea Pedis Treatment Market Set for Robust Growth, Projected to Reach USD 2,484 Million by 2034 at a 5.2% CAGR

The global tinea pedis treatment market is on a strong growth trajectory, with the industry expected to be valued at USD 1,496.3 million in 2024. According to the latest market analysis, the demand for tinea pedis treatments is forecasted to expand at a compound annual growth rate (CAGR) of 5.2%, leading the market to achieve a total valuation of USD 2,484 million by 2034.

Tinea pedis, commonly known as athlete’s foot, is a prevalent fungal infection affecting millions worldwide. The increasing prevalence of this condition, combined with growing awareness about its treatment options, is driving the market’s expansion. Advances in antifungal medications, both topical and oral, as well as innovative treatment modalities, are contributing to the market’s robust growth.

The rise in healthcare expenditure and the introduction of new, more effective treatments are expected to fuel the demand further. Additionally, the expansion of healthcare infrastructure in emerging markets and a surge in preventive health measures are anticipated to positively influence market dynamics.

“The global tinea pedis treatment market is experiencing significant growth, driven by an increasing awareness of fungal infections and advancements in treatment options,” said FMI. “Our ongoing commitment to innovation and patient care is aligned with the growing demand for effective solutions, and we are excited to contribute to this expanding market.”

As the market continues to evolve, key players in the industry are focusing on research and development to introduce novel therapies and improve existing treatments. This approach aims to address the diverse needs of patients and enhance the overall effectiveness of tinea pedis management.

Key Takeaways from the Market Study:

The global tinea pedis treatment industry is set to advance at 2% CAGR through 2034.
By disease indication, the interdigital tinea pedis is forecast to account for a share value of 4% in 2024.
By route of administration, the topical segment will likely hold a value share of 4% in 2024.
By distribution channel, the hospital pharmacies segment is anticipated to hold a market share of 4% in 2024.
By drug class, the antifungal category dominates the market, accounting for 8% of the market share value in 2023.
The United States is poised to exhibit a CAGR of 2% through 2034.
Demand in China is predicted to increase at 3% CAGR between 2024 and 2034.

“Medical research has fuelled the creation of potent topical antifungal creams and ointments specifically tailored to combat tinea pedis. Development of these new enhanced formulations will bode well for the industry during the assessment period,” says a lead analyst of Future Market Insights (FMI).

Explore the Growing Demand for Tinea Pedis Treatment: Get All the Insights in Our Comprehensive Report!

Who is Winning?

Glenmark Pharmaceuticals Inc., USA, McKesson (NorthStar Rx LLC), Camber Pharmaceuticals, Inc., Sebela Pharmaceuticals, Inc., Blueberry Therapeutics Ltd., Exeltis USA, Inc., Viatris (Mylan N.V.), Bayer AG, GlaxoSmithKline Plc (GSK), and Novartis AG are few of the leading players listed in the report.

Top companies are constantly striving to develop new antifungal medications with enhanced antifungal activity, reduced side effects, and improved skin compatibility. They are also implementing strategies like acquisitions, distribution agreements, and partnerships to stay ahead of the competition.

Industry Updates:

In January 2024, Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. entered into a definitive merger agreement.
In September 2023, Aurobindo Pharma announced that it was entering the Indonesian market by acquiring 15 formulation brands from Pfizer Inc. and Viatris Inc.

Key Segments of Market Report:

By Disease Indication:

As per disease indication, the industry has been categorized into interdigital tinea pedis, plantar tinea pedis, and vesicular tinea pedis.

By Route of Administration:

Based on route of administration, the report is segmented into topical and oral. The topical segment is further divided into gel, cream, spray, lotion, and powder.

By Distribution Channel:

Different distribution channels include hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.

By Drug Class:

In terms of drug class, the industry is categorized into antifungals and combinations.

By Region:

Industry analysis has been carried out in key countries of North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East and Africa.

About Future Market Insights (FMI)

Contact Us: